Nearly 70% of Akcea's workforce is on the chopping block as Ionis executes major restructuring

Nicole DeFeudis

Editor

About half a year after reabsorbing its lipid-focused spinout Akcea, Ionis is now putting a major reorganization plan in play — one that involves shaving …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nearly 70% of Akcea's workforce is on the chopping block as Ionis executes major restructuring

Nicole DeFeudis

Editor

Sign up to read this article for free.

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Merck’s long-awaited obesity move is an oral GLP-1 from China

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total

Near­ly 70% of Akcea's work­force is on the chop­ping block as Io­n­is ex­e­cutes ma­jor re­struc­tur­ing

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure?

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

Nearly 70% of Akcea's workforce is on the chopping block as Ionis executes major restructuring

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Merck’s long-awaited obesity move is an oral GLP-1 from China

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total